Zeyu Zhao,Fang Song,Shunsuke Kimura,Takeshi Onodera,Takahiro Uchida,Kiyoshi Toko
Abstract:Taste sensors with an allostery approach have been studied to detect non-charged bitter substances, such as xanthine derivatives, used in foods (e.g., caffeine) or pharmaceuticals (e.g., etofylline). In this study, the authors modified a taste sensor with 3-bromo-2,6-dihydroxybenzoic acid and used it in conjunction with sensory tests to assess the bitterness of non-charged pharmaceuticals with xanthine scaffolds (i.e., acefylline and doxofylline), as well as allopurinol, an analogue of hypoxanthine. The results show that the sensor was able to differentiate between different levels of sample bitterness. For instance, when assessing a 30 mM sample solution, the sensor response to acefylline was 34.24 mV, which corresponded to the highest level of bitterness (τ = 3.50), while the response to allopurinol was lowest at 2.72 mV, corresponding to relatively weaker bitterness (τ = 0.50). Additionally, this study extended the application of the sensor to detect pentoxifylline, an active pharmaceutical ingredient in pediatric medicines. These results underscore the taste sensor's value as an additional tool for early-stage assessment and prediction of bitterness in non-charged pharmaceuticals.
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve
This paper aims to evaluate the bitterness of non-charged drugs, particularly those with a xanthine skeleton (such as acefylline and doxofylline) and allopurinol. Specifically, the researchers developed a taste sensor based on an allosteric mechanism and enhanced the sensor's ability to detect non-charged bitter substances through surface modification (using 3-bromo-2,6-dihydroxybenzoic acid, 3-Br-2,6-DHBA).
### Main Research Content
1. **Background Introduction**:
- The bitterness of drugs is an important factor, especially in pediatric medications, as bitterness can affect patient acceptance and compliance.
- Traditional sensory tests have ethical and safety issues, particularly with drugs lacking toxicity data.
- Taste sensors (electronic tongues) have shown potential in evaluating drug bitterness, but existing sensors (such as BT0) have limited sensitivity to non-charged bitter substances.
2. **Methods and Techniques**:
- The researchers developed a new taste sensor using 3-Br-2,6-DHBA as a membrane modifier to improve the detection sensitivity of non-charged bitter substances.
- The bitterness intensity of different concentrations of acefylline, doxofylline, and allopurinol was evaluated through electrochemical responses and sensory tests.
3. **Experimental Results**:
- The 3-Br-2,6-DHBA modified sensor showed significant responses to non-charged bitter substances (such as caffeine, acefylline, doxofylline, and pentoxifylline), while the commercial BT0 sensor showed no response to these substances.
- At different concentrations, the sensor's response to acefylline and doxofylline was positively correlated with sensory test results, consistent with the Weber-Fechner law.
- For allopurinol, the 3-Br-2,6-DHBA modified sensor also showed a concentration-dependent response, indicating a weak bitterness.
4. **Conclusion**:
- The 3-Br-2,6-DHBA modified taste sensor can effectively detect the bitterness of non-charged drugs, providing a new tool for early evaluation and prediction of drug bitterness.
- This sensor has high accuracy and reliability in clinical applications, particularly in pediatric medications and drugs requiring local application.
### Summary
This paper addresses the issue of existing sensors' insufficient ability to detect non-charged bitter substances by developing a new type of taste sensor, providing strong support for drug development and formulation optimization.